Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 20/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mrk-560 SCHEMBL29358202 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Mrk-560 SCHEMBL237759 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| Mrk-560 SCHEMBL237758 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8257641 | 0.91 | PSEN1 (0.83) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8255498 | 0.90 | PSEN1 (0.82) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15808652 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8001446 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1079669 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL15808651 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1247059 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| WO-2024112356-A1 | METHODS FOR TREATING RESPIRATORY DISEASES CHARACTERIZED BY MUCUS HYPERSECRETION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-05-30 | — | — | WO | claimed |
| US-20240117303-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2024-04-11 | — | — | US | claimed |
| US-20240091300-A1 | CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR | THE PENN STATE RESEARCH FOUNDATION (US) | 2024-03-21 | — | — | US | claimed |
| WO-2024019800-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-01-25 | — | — | WO | claimed |
| US-11850273-B2 | Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair | THE PENN STATE RESEARCH FOUNDATION (US) | 2023-12-26 | — | — | US | claimed |
| US-20230277550-A1 | Methods for Treating Respiratory Diseases Characterized by Mucus Hypersecretion | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | claimed |
| EP-4199914-A2 | METHODS FOR TREATING RESPIRATORY DISEASES CHARACTERIZED BY MUCUS HYPERSECRETION | The Board of Trustees of the Leland Stanford Junior University (US) | 2023-06-28 | — | — | EP | claimed |
| CN-116033895-A | Method for treating respiratory diseases characterized by mucus hypersecretion | 小利兰·斯坦福大学托管委员会 | 2023-04-28 | — | — | CN | claimed |
| US-11466252-B2 | Expansion and differentiation of inner ear supporting cells and methods of use thereof | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2022-10-11 | — | — | US | claimed |
| CN-109251894-B | Chemical reprogramming of human glial cells into neural cells for brain and spinal cord repair | 宾州研究基金会 | 2022-10-04 | — | — | CN | claimed |
| WO-2022040447-A9 | METHODS FOR TREATING RESPIRATORY DISEASES CHARACTERIZED BY MUCUS HYPERSECRETION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2022040447-A2 | METHODS FOR TREATING RESPIRATORY DISEASES CHARACTERIZED BY MUCUS HYPERSECRETION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-24 | — | — | WO | claimed |
| US-20200224159-A1 | UNIFIED CELL DIFFERENTIATION PROTOCOL | EYESTEM RESEARCH PRIVATE LIMITED (IN) | 2020-07-16 | — | — | US | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850273-B2 | Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair | BMP4, GSK3B, PYGB | PSEN1 19/4885PSEN2 30/4885APH1B 27/4885 |
| US-20240091300-A1 | CHEMICAL REPROGRAMMING OF HUMAN GLIAL CELLS INTO NEURONS FOR BRAIN AND SPINAL CORD REPAIR | BMP4, GSK3B, PYGB | PSEN1 19/4885PSEN2 32/4885APH1B 27/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | PSEN1 3727/4885PSEN2 4120/4885APH1B 630/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.